9 December 2021

SyVento and OncoArendi agreement

SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02.
Details in following press release.

We use cookies and similar technologies, including for the purposes of: providing services, advertising, statistics. Using the site without changing your browser settings means that they will be placed on your end device. Remember that you can always change these settings.